Form 4: Insmed CEO William Lewis Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Insmed's CEO, William Lewis, exercised stock options and sold shares of common stock on February 3, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On February 3, 2025, William Lewis, the Chair and CEO of Insmed Inc., executed stock options and sold shares of Insmed's common stock.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan.
- Lewis exercised options to acquire 18,750 shares at $22.76 and 6,830 shares at $10.85.
- He then sold 241 shares at a weighted average price of $75.25, 1,872 shares at $76.35, 9,869 shares at $77.97, 6,768 shares at $78.44, 41 shares at $74.86, 745 shares at $76.43, 3,463 shares at $77.95 and 2,581 shares at $78.40.
- Following these transactions, Lewis directly owns 379,534 shares of common stock and indirectly owns 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
- He also directly owns options for 56,250 shares and indirectly owns options for 211,800 shares through the Katie Procter Dynasty Trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
This filing is a routine disclosure of insider transactions, which are common among executives of publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- Insider transactions are a normal part of executive compensation at publicly traded companies like Insmed.
- Companies such as Amgen, Gilead Sciences, and Biogen also see regular Form 4 filings from their executives.
- The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations, similar to what is seen at companies like Vertex Pharmaceuticals and Regeneron.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests the sales were planned and not based on any sudden change in the company's outlook.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of earliest transaction: exercise of stock options and sale of common stock. |
| 02/05/2025 | Date of signature for the Form 4 filing. |
| 05/21/2025 | Expiration date of some stock options. |
| 05/19/2026 | Expiration date of some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.